Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer

Wójcik, Ewa; Tarapacz, J.; Rychlik, Urszula; Stasik, Zofia; Sas-Korczyńska, Beata; Skotnicki, Piotr; Kulpa, J

doi:10.7754/clin.lab.2016.151212

Cited by 15 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 492 items were identified (212 from PubMed, 262 from Embase, and 18 from the Cochrane library). After meticulous screening and inspection of the articles, finally, 18 articles were included in our final analysis [21,[25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41]. Table 1 summarizes the characteristics of the included studies.…”

Section: Study Characteristicsmentioning

confidence: 99%

Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background: Neuron-specific enolase (NSE) has become a widely used and easily attainable laboratory assay of small cell lung cancer (SCLC). However, the prognostic value of NSE for SCLC patients remains controversial. The aim of the study was to evaluate the correlation between elevated serum NSE before therapy and survival of SCLC patients. Methods: We performed a systematic review and meta-analysis. A systematic literature search was conducted in PubMed, Embase, and the Cochrane Central Register from the inception dates to December 2019. Eligible articles were included according to inclusion and exclusion criteria; then, data extraction and quality assessment were performed. The primary outcome was overall survival (OS), and the secondary endpoint was progression-free survival (PFS). Results: We identified 18 studies comprising 2981 patients. Pooled results revealed that elevated NSE was associated with worse OS (HR = 1.78, 95% CI 1.55-2.06, p < 0.001) and PFS (HR = 1.50, 95% CI 1.16-1.93, p = 0.002). In subgroup analysis, elevated NSE did not predict worse OS in patients who received only chemotherapy (HR 1.22, 95% CI 0.96-1.55, p = 0.10) or part of whom received surgical resection before chemotherapy and radiotherapy (HR = 2.16, 95% CI 0.82-5.69, p = 0.12). Conclusion: Elevated serum NSE before any therapy of SCLC patients may be a negative prognostic factor for OS and PFS. The prognostic value of NSE for OS was particularly observed in patients treated by standard management.

show abstract

Section: Study Characteristicsmentioning

confidence: 99%

Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Our observation may be explained that all SCLC patients had bone metastases. Previous studies showed that HE4 is a potential marker for the diagnosis and follow up of NSCLC patients and could be helpful in evaluation of SCLC patient´s prognosis [43,44]. Celik and Bulut observed that HE4 is expressed in adenocarcinoma tissues but it is not frequent in SCLC [45].…”

Section: Discussionmentioning

confidence: 99%

The value of human epididymis protein 4 (HE4) as a serum tumor marker for accurate bone metastases finding by whole-body bone scintigraphy in lung cancer patients

Weissensteiner¹,

Babušíková

2019

neo

View full text Add to dashboard Cite

The aim of our study was to correlate the serum concentration of human epididymis protein 4 (HE4) in lung cancer patients with the bone metastases detected by whole-body bone scintigraphy. The serum concentrations of HE4 were determined by electrochemiluminescence immunoassay (ELISA) method in 60 patients with lung cancer and in 10 persons without malignant disease (control group). All participants were examined by whole-body bone scintigraphy with hybrid gamma camera of type BrightView XCT. We found bone metastases in 25.0% of patients by whole-body bone scintigraphy and probable bone metastases in 18.3% of patients. We did not observe bone metastases in 56.7% of patients and in nobody from control group. We observed that 73.33% patients with bone metastases had more than 3 bone metastasis deposits. Patients had significantly increased concentration of HE4 (p<0.0001). All three subgroups of patients (bone metastases, probable bone metastases, no evidence of bone metastases) had significantly increased concentration of HE4 compared to controls. The highest concentration of HE4 had 9 patients with small-cell lung cancer of whose 4 patients had bone metastases, 4 patients had probable bone metastases and one patient was with no evidence of bone metastases. We found that HE4 has a discriminatory ability to differentiate groups of patients and healthy controls, as well as within scaffold scintigraphy in patients with lung cancer (p=0.0002). The serum concentration of human epididymis protein 4 was significantly increased in patients with lung cancer in comparison with persons of control group. A quarter of lung cancer patients had identified bone metastases by whole-body bone scintigraphy and approximately 20% of patients had probable bone metastases. The increasing serum concentrations of human epididymis protein 4 can have importance in the diagnosis of bone metastases in patients with lung cancer, in particular in small-cell lung cancer.

show abstract

“…A recent study was conducted on SCLC using HE4 assays to analyze the serum of 63 patients with SCLC, compared to 66 controls (10). The AUC for HE4 was 0.884.…”

Section: Discussionmentioning

confidence: 99%

“…Its sensitivity (43.8-69.4%) and specificity (78.5-95.0%) for lung cancer detection (6,7,8) has been previously identified and its increase in the serum after postoperative period was found to correlate with recurrence (9). Its serum concentration is also associated with tumor stage, and disease progression occurred within the first year in patients with small-cell lung cancer (SCLC) (10). Among locally advanced non-small cell lung cancer (NSCLC) patients, a higher serum level of HE4 has been found to predict non-responders to chemoradiotherapy (11).…”

Section: Introductionmentioning

confidence: 99%

Human epididymis protein 4 may not be a reliable screening biomarker for detecting lung carcinoma patients

Çelik

Bulut

2017

Biomedical Reports

View full text Add to dashboard Cite

Abstract. Human epididymis protein 4 (HE4) acts as a protease inhibitor. It has been detected in the serum of patients with lung cancer patients and its utility for lung cancer screening was found in different studies. Nevertheless, little is known regarding the expression of HE4 in lung carcinoma subtypes. The aim of the present study was to investigate whether HE4 expression is a reliable marker for detecting any lung carcinoma subtypes, including small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and adenocarcinoma (AC). In total, 141 lung carcinoma patients were enrolled in the study. Biopsy samples were obtained from bronchoscopic biopsy. The tumors were classified as SCLC (group 1, 54 cases) or NSCLC (group 2, 87 cases) based on histology and immunohistochemistry. The latter was sub-grouped as adenocarcinoma (group 2a, AC) and squamous cell carcinoma (group 2b, SCC). The immunohistochemical expression of HE4 was compared between the groups. The study revealed that the majority of the SCLC and SCC cases were devoid of HE4 (90.1 and 89.65%, respectively). Approximately 10% of cases had HE4 immune expression and the staining was focal and moderate throughout the tumor tissue. On the other hand, 78.8% of AC expressed HE4 and the staining was diffuse and strong. The overall HE4 expression in the lung cancer patients was 33.7%. In conclusion, the results of the present study have shown that HE4 is expressed in adenocarcinoma of the lung but it is not frequent in SCC and SCLC. The value of HE4 as a screening biomarker for lung cancer is limited but its presence exclusively in adenocarcinoma may provide new insight for targeted therapy.

show abstract

Human Epididymis Protein 4 (HE4) in Patients with Small-Cell Lung Cancer

Abstract: Diagnostic utility of HE4 was similar to that of NSE and ProGRP. Complementary to NSE, determination of HE4 seems to be helpful in evaluation of SCLC patients' prognosis.

Cited by 15 publications

References 0 publications

Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis

Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis

The value of human epididymis protein 4 (HE4) as a serum tumor marker for accurate bone metastases finding by whole-body bone scintigraphy in lung cancer patients

Human epididymis protein 4 may not be a reliable screening biomarker for detecting lung carcinoma patients

Contact Info

Product

Resources

About